TRDA Live signals | Maximize Profits with Getagraph.com

BUY 159428 min ago

@ $14.49

Issued: 13 Feb 2024 @ 09:30

Return: 6.76%

Previous signal: Feb 7 - 09:30

Previous signal: Sell

Return: 1.26 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases...

Stats
Today's Volume	83 381.00
Average Volume	75 930.00
Market Cap	522.25M
EPS	$0 ( 2024-05-08 )
Next earnings date	( $0.120 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	22.42
ATR14	$0.0600 (0.39%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-16	Sethuraman Natarajan	Sell	1 000	Common Stock
2024-05-17	Sethuraman Natarajan	Sell	8 305	Common Stock
2024-05-20	Sethuraman Natarajan	Sell	9 675	Common Stock
2024-05-16	Doshi Dipal	Sell	1 800	Common Stock
2024-05-17	Doshi Dipal	Sell	1 200	Common Stock

INSIDER POWER
73.17
Last 99 transactions
Buy: 998 278 \| Sell: 169 698

Volume Correlation

Long: 0.06 (neutral)

Short: -0.64 (weak negative)

Signal:(45.079) Neutral

Entrada Therapeutics, Correlation

10 Most Positive Correlations
KRKR	0.822
BKSC	0.813
MSEX	0.811
SMPL	0.808
USCB	0.805
DSWL	0.802
HONE	0.801

10 Most Negative Correlations
ARQT	-0.832
PYXS	-0.83
META	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Entrada Therapeutics, Correlation - Currency/Commodity

-0.02
( neutral )

-0.35
( neutral )

-0.41
( neutral )

0.03
( neutral )

0.71
( moderate )

Entrada Therapeutics, Financials

Annual	2023
Revenue:	$129.01M
Gross Profit:	$126.17M (97.80 %)
EPS:	$-0.200

FY	2023
Revenue:	$129.01M
Gross Profit:	$126.17M (97.80 %)
EPS:	$-0.200

FY	2022
Revenue:	$0
Gross Profit:	$-1.90M (0.00 %)
EPS:	$-2.79

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.97

Financial Reports:

No articles found.

Entrada Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Entrada Therapeutics,

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.